Top

Published in:

Open Access 01-01-2014 | Original Article

Telbivudine and adefovir combination therapy for patients with chronic lamivudine-resistant hepatitis B virus infections

Authors: Ming-Tsung Lin, Yeh-Pin Chou, Tsung-Hui Hu, Hsien-Chung Yu, Yu-Chun Hsu, Ming-Chao Tsai, Po-Lin Tseng, Kuo-Chin Chang, Yi-Hao Yen, King-Wah Chiu

Published in: Archives of Virology | Issue 1/2014

Abstract

We evaluated second-line salvage therapy with adefovir + telbivudine (group 1), adefovir followed by adefovir + telbivudine (group 2), or lamivudine + adefovir followed by adefovir + telbivudine (group 3) in hepatitis B patients with an inadequate virologic response to lamivudine treatment. Simple linear regression analysis showed that for each additional month of treatment, the most significant reduction in viral load occurred in group 1 (HBV DNA [Log₁₀ IU/mL]: group 1, −0.149; group 2, -0.081; group 3, −0.123). Generalized estimating equation analysis revealed that compared to group 1, hepatitis B virus (HBV) DNA levels were 1.203 and 0.443 Log₁₀ IU/mL higher in groups 2 and 3, respectively. Overall, a significant reduction in viral load (−0.060 Log₁₀ IU/mL) was observed for each additional month of treatment. Adefovir + telbivudine treatment resulted in a significant reduction in HBV DNA levels. Moreover, telbivudine treatment resulted in a significant reduction in viral load (−0.050 Log₁₀ IU/mL) compared to lamivudine treatment after the emergence of lamivudine resistance.

Available only for authorised users

Hepatitis B Fact Sheet N°204 (2008) World Health Organization. http://www.who.int/mediacentre/factsheets/fs204/en/index.html

Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, Tobias H, Wright TL (2006) A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 4:936–962PubMedCrossRef

Lok AS, Zoulim F, Locarnini S, Bartholomeusz A, Ghany MG, Pawlotsky JM, Liaw YF, Mizokami M, Kuiken C, Hepatitis B Virus Drug Resistance Working Group (2007) Antiviral drug-resistant HBV: Standardization of nomenclature and assays and recommendations for management. Hepatology 46:254–265PubMedCrossRef

Pais R, Benhamou Y (2010) Long-term therapy for chronic hepatitis B in HIV co-infected patients. Gastroenterol Clin Biol 34(Suppl 2):S136–S141PubMedCrossRef

Wang Q, Yang L, Mo L (2007) The evaluation and prediction of the effect of AIDS therapy. IEEE/ICME. 1591–1596

Sloan RD, Ijaz S, Moore PL, Harrison TJ, Teo CG, Tedder RS (2008) Antiviral resistance mutations potentiate hepatitis B virus immune evasion through disruption of its surface antigen a determinant. Antivir Ther 13:439–447PubMed

Shaw T, Bartholomeusz A, Locarnini S (2006) HBV drug resistance: mechanisms, detection and interpretation. J Hepatol 44:593–606PubMedCrossRef

Zoulim F (2004) Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection. Antiv Res 64:1–15

Kukko C. HBV: Drugs in current clinical development. HCSP Version 4.1, August 2008

10.

Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y et al (2007) Telbivudine versus lamivudine in patients with chronic hepatitis B. N Eng J Med 357:2576–2588CrossRef

11.

Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, Heathcote EJ, Manns M, Bzowej N, Niu J, Han SH, Hwang SG, Cakaloglu Y, Tong MJ, Papatheodoridis G, Chen Y, Brown NA, Albanis E, Galil K, Naoumov NV, GLOBE Study Group (2009) 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 136:486–495PubMedCrossRef

12.

Tsai MC, Chen CH, Lee CM, Chen YT, Chien YS, Hung CH, Wang JH, Lu SN, Yen YH, Changchien CS, Hu TH (2009) The role of HBV genotype, core promoter and precore mutations in advanced liver disease in renal transplant recipients. J Hepatol 50:281–288PubMedCrossRef

13.

Wang M, Long Q (2011) Modified robust variance estimator for generalized estimating equations with improved small-sample performance. Stat Med 30:1278–1291PubMedCrossRef

14.

Martus P, Stroux A, Jünemann AM, Korth M, Jonas JB, Horn FK, Ziegler A (2004) GEE approaches to marginal regression models for medical diagnostic tests. Stat Med 23:1377–1398PubMedCrossRef

15.

Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, Dienstag JL, Heathcote EJ, Little NR, Griffiths DA, Gardner SD, Castiglia M (2003) Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 125:1714–1722PubMedCrossRef

16.

Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Chien RN, Dent J, Roman L, Edmundson S, Lai CL (2000) Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 119:172–180PubMedCrossRef

17.

Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, Lim SG, Wu PC, Dent JC, Edmundson S, Condreay LD, Chien RN, Asia Hepatitis Lamivudine Study Group (2001) Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy. Hepatology 33:1527–1532PubMedCrossRef

18.

Brunelle MN, Jacquard AC, Pichoud C, Durantel D, Carrouée-Durantel S, Villeneuve JP, Trépo C, Zoulim F (2005) Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 41:1391–1398PubMedCrossRef

19.

Sheldon J, Rodès B, Zoulim F, Bartholomeusz A, Soriano V (2006) Mutations affecting the replication capacity of the hepatitis B virus. J Viral Hepat 13:427–434PubMedCrossRef

20.

Andreone P, Gramenzi A, Cursaro C, Biselli M, Cammà C, Trevisani F, Bernardi M (2004) High risk of hepatocellular carcinoma in anti-HBe positive liver cirrhosis patients developing lamivudine resistance. J Viral Hepat 11:439–442PubMedCrossRef

21.

Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J, Cirrhosis Asian Lamivudine Multicentre Study Group (2004) Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Eng J Med 351:1521–1531CrossRef

22.

Fung SK, Chae HB, Fontana RJ, Conjeevaram H, Marrero J, Oberhelman K, Hussain M, Lok AS (2006) Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 44:283–290PubMedCrossRef

23.

Yeon JE, Yoo W, Hong SP, Chang YJ, Yu SK, Kim JH, Seo YS, Chung HJ, Moon MS, Kim SO, Byun KS, Lee CH (2006) Resistance to adefovir dipivoxil (ADV) in lamivudine resistant chronic hepatitis B patients treated with ADV. Gut 55:1488–1495PubMedCrossRef

24.

Lee YS, Suh DJ, Lim YS, Jung SW, Kim KM, Lee HC, Chung YH, Lee YS, Yoo W, Kim SO (2006) Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 43:1385–1391PubMedCrossRef

25.

Chen CH, Wang JH, Lee CM, Hung CH, Hu TH, Wang JC, Lu SN, Changchien CS (2006) Virological response and incidence of adefovir resistance in lamivudine-resistant patients treated with adefovir dipivoxil. Antivir Ther 11:771–778PubMed

26.

Lampertico P, Viganò M, Manenti E, Iavarone M, Sablon E, Colombo M (2007) Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 133:1445–1451PubMedCrossRef

27.

Aizawa M, Tsubota A, Fujise K, Tatsuzawa K, Kono M, Hoshina S, Tajiri H (2011) Clinical course and predictive factors of virological response in long-term lamivudine plus adefovir dipivoxil combination therapy for lamivudine-resistant chronic hepatitis B patients. J Med Virol 83:953–961PubMedCrossRef

28.

Min AD, Dienstag JL (2007) Oral antivirals for chronic hepatitis B. Clin Liver Dis 11:851–868PubMedCrossRef

29.

Tenney DJ (2010) Genotypic determinants and phenotypic properties of antiviral-resistant HBV variants: insight from entecavir resistance studies. Antivir Ther 15:529–535PubMedCrossRef

30.

Lok AS, McMahon BJ (2009) Chronic hepatitis B: update 2009. Hepatology 50:661–662PubMedCrossRef

31.

Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH, REVEAL-HBV Study Group (2006) Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295:65–73PubMedCrossRef

32.

Doo E, Liang JT (2001) Molecular anatomy and pathophysiologic implications of drug resistance in hepatitis B virus infection. Gastroenterology 120:1000–1008PubMedCrossRef

Title: Telbivudine and adefovir combination therapy for patients with chronic lamivudine-resistant hepatitis B virus infections
Authors: Ming-Tsung Lin
Yeh-Pin Chou
Tsung-Hui Hu
Hsien-Chung Yu
Yu-Chun Hsu
Ming-Chao Tsai
Po-Lin Tseng
Kuo-Chin Chang
Yi-Hao Yen
King-Wah Chiu
Publication date: 01-01-2014
Publisher: Springer Vienna
Published in: Archives of Virology / Issue 1/2014
Print ISSN: 0304-8608
Electronic ISSN: 1432-8798
DOI: https://doi.org/10.1007/s00705-013-1786-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2014

A suggested classification for two groups of Campylobacter myoviruses

Dynamics and evolution of porcine reproductive and respiratory syndrome virus (PRRSV) ORF5 following modified live PRRSV vaccination in a PRRSV-infected herd

Complete genome sequence of marine bacterium Pseudoalteromonas phenolica bacteriophage TW1

The effect of cell line, phylogenetics and medium on baculovirus budded virus yield and quality

Retrospective serosurveillance of bovine norovirus (GIII.2) and nebovirus in cattle from selected feedlots and a veal calf farm in 1999 to 2001 in the United States

Effects of equid herpesvirus 1 (EHV-1) AR8 and HH1 strains on BALB-c mice

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials